The US Food and Drug Administration has authorized two vaccines — one developed by Moderna and one by Pfizer-BioNTech — to fight COVID-19, but a number of drug companies and laboratories are looking to throw another candidate into the mix. Here’s more information on the vaccine front-runners, including their estimated efficacy, dose regimen, and clinical trial timeline.
As Massachusetts embarks on a mission to vaccinate all of its residents, the Globe is also keeping tabs on how many people and which groups are getting the vaccine. You can use this interactive page to explore the data.
Click here for more of the Globe’s COVID-19 coverage and resources.
Each prospective vaccine goes through three phases of study in humans, and to speed the process, some developers are conducting two phases simultaneously.
Phase 1: Trials involve small numbers of people, testing whether the vaccine is safe and provokes an immune response.
Phase 2: Trials expand to hundreds of people, comparing the vaccine’s effects in different groups and further testing its safety.
Phase 3: Trials enroll many thousands of people, to see if those who receive the vaccine are less likely to become infected than those who receive a placebo.
Emergency Use Authorization: The FDA is granting COVID-19 vaccine candidates emergency use authorization, which means they can be used even though they have not been officially approved.
Below is a subset of notable vaccine candidates that either have ties to New England, have major funding behind them and the ability to move markets, or reflect a diversity of approaches.
Efficacy: 94.1 percent
Dose: 2 shots, 4 weeks apart
The FDA cleared Moderna’s vaccine for emergency use on Dec. 18, a week after Pfizer’s authorization, making it the second vaccine available in the US. A panel of outside experts recommended the FDA authorize Moderna’s vaccine the day before. The vaccine has since been authorized in Canada, Israel, and the European Union.
Moderna said Jan. 25 that its two-dose vaccine generates a weaker immune response against a strain of the disease that first emerged in South Africa, prompting the firm to plan a clinical trial in the United States of a “booster” shot that recipients would receive.
On Jan. 19, Maine and Michigan reported that they may need to dispose of 16,000 Moderna vaccines, which may have spoiled due to temperature problems in transportation. A day later, New York Mayor Bill de Blasio said the city is experiencing supply shortages with the Moderna vaccine, resulting in 23,000 rescheduled vaccine appointments. Moderna said the the distribution problems are beyond its control.
As of Jan. 26, Moderna said that it has supplied the US government with 30.4 million doses of its vaccine. The US has agreed to purchase 200 million doses of the vaccine with options for an additional 300 million.
The company confirmed it is on track to deliver 100 million doses to the US by the end of the first quarter and “potentially 1 billion doses for 2021.”
Approach: The Moderna technology — called messenger RNA — inserts portions of the virus’s RNA into cells, which then manufacture a piece of the virus to trigger an immune response. The company set a drug industry record by producing its vaccine in 42 days after receiving the genetic sequence of the virus that causes COVID-19.
Funding: On Aug. 11, the government awarded Moderna $1.5 billion for 100 million doses if the vaccine proves safe and effective. This funding came in addition to the almost $1 billion already provided by the Biomedical Advanced Research and Development Authority.
Updated Jan. 26
Pfizer and BioNTech
Status of clinical trials: Authorized for use in US, UK, Canada, other countries. Phase 3 trial
Efficacy: 95 percent
Dose: 2 shots, 3 weeks apart
The FDA authorized emergency use of the Pfizer-BioNTech COVID-19 vaccine on Dec. 11, the first vaccine authorized in the US.
When it was cleared in the US, it already had been authorized elsewhere: Britain’s drug regulator granted Pfizer its first emergency-use approval on Dec. 2, and Bahrain said it became the second later that week. On Dec. 9, Canada’s health regulator approved the vaccine, and it was cleared in Mexico on Dec. 11.
According to early findings of a study published Jan. 7, the Pfizer-BioNTech vaccine appears to work against a key mutation found in two highly contagious strains of the illness.
Documents released by the FDA on Dec. 8 suggest the Pfizer vaccine candidate provides strong protection against COVID-19 after the first dose, but experts said they still recommend patients get the second shot. On Dec. 23, Pfizer and BioNTech agreed in a nearly $2 billion deal to supply the US with an additional 100 million doses of the vaccine. The companies already had a contract to supply 100 million doses to the US under Operation Warp Speed.
Approach: Pfizer, which has a manufacturing plant in Andover, is deploying technology similar to Moderna’s: a messenger RNA vaccine that codes for the spike protein found on the surface of the coronavirus. BioNTech’s US headquarters is located in Cambridge.
Funding: Pfizer agreed to pay BioNTech $185 million upfront, and BioNTech has a debt financing agreement with the European Investment Bank.
Updated Jan. 7
AstraZeneca and the University of Oxford
Status of clinical trials: Authorized for use in UK, Argentina, India, Mexico. Phase 3 in the United Kingdom, Brazil, South Africa
Efficacy: 82.4 percent
Dose: 2 shots, 12 weeks apart
South Africa halted the use of the vaccine from AstraZeneca and the University of Oxford on Feb. 7 after evidence showed the drug was not effective against a virus variant. Instead, the country said on Feb. 10 that it would vaccinate front-line health workers with the Johnson & Johnson shot, which is still in testing. The same day, an advisory panel to the World Health Organization expressed confidence in AstraZeneca’s vaccine, despite the virus variant concerns.
The companies released a report in February that suggests the vaccine an efficacy rate of 82.4 percent if administered twice 12 weeks apart.
The results from a peer-reviewed study on the vaccine candidate published Dec. 8 suggest it is about 70 percent effective, but questions remain as to how well it works in older populations. The company temporarily halted its vaccine trails on Sept. 6 due to suspected adverse reaction in a participant.
Approach: In a partnership with the University of Oxford, the British-Swedish company has developed a vaccine that uses a weakened version of a common-cold virus to deliver coronavirus genes into cells to provoke an immune response.
Funding: BARDA has provided more than $1 billion in funding.
Updated Feb. 10
Johnson & Johnson
Status of clinical trials: Phase 3 trial began in September
Efficacy: 72 percent
Dose: 1 shot
Johnson & Johnson’s one-shot COVID-19 vaccine appears to provide more protection against worrisome virus variants than the drug giant initially reported, according to new trial data released on Feb. 24 advance of a Friday advisory panel meeting on whether to recommend the vaccine as the third cleared for emergency use in the US.
Johnson & Johnson asked US regulators to clear its one-shot vaccine for emergency use on Feb. 4. It is the first step in a regulatory process that that could lead to the rollout of the third COVID-19 vaccine in the US within a few weeks.
Johnson & Johnson said Jan. 29 that its vaccine is 66 percent effective in preventing moderate and severe global COVID-19 cases.
The US government said it would commit $1 billion for 100 million J&J doses if the vaccine is authorized.
On Oct. 12, STAT reported the study was paused due to an unexplained illness in a study participant, but the trial has since resumed. In November, J&J said it also began a clinical trial that would test the vaccine’s efficacy at two doses, instead of one.
Approach: The company developed the vaccine with the Center for Virology and Vaccine Research at Beth Israel Deaconess Medical Center in Boston. The vaccine uses a common-cold virus to deliver part of the coronavirus into cells to stimulate the immune system to fight off an infection.
Funding: In addition to the $1 billion commitment from the federal government, J&J and BARDA have invested more than $1 billion in the effort.
Updated Feb. 4
Status of clinical trials: Phase 3 in the United Kingdom and US
Efficacy: 89 percent
Dose: 2 shots, 3 weeks apart
Novavax said on Jan. 28 its COVID-19 vaccine appears 89 percent effective based on early findings from a study in the UK.
Novavax began a Phase 3 trial with 30,000 people in the US and Mexico for its COVID-19 vaccine candidate on Dec. 28. Its other Phase 3 trial in the UK began in September, and the company said early results are expected in the first quarter of 2021.
On Nov. 9, the FDA granted Maryland-based Novavax “Fast Track Designation” for its vaccine.
Approach: The company is expanding its manufacturing capacity and pursuing late-stage clinical trials. Its vaccine candidate uses protein nanoparticles, together with a proprietary compound, to generate and enhance the immune response.
Funding: The firm has been awarded $1.6 billion by the US government’s Operation Warp Speed, and previously received $388 million from the Coalition for Epidemic Preparedness Innovations.
Updated Jan. 28
Status of clinical trials: Phase 2/3 in Germany
Dose: 2 shots, 4 weeks apart
Drugmaker GlaxoSmithKline said on Feb. 3 that it would help CureVac manufacture 100 million doses its vaccine candidate this year. GSK will also invest $181 million to support CureVac research aimed at developing new vaccines that target emerging COVID-19 variants.
Approach: The firm, which has about 20 employees at its US hub in Boston, is manufacturing a vaccine candidate that relies on messenger RNA.
Funding: CureVac has received an $85 million loan from the lending arm of the European Union and a grant of up to $8.3 million from the Coalition for Epidemic Preparedness Innovations.
Updated Feb. 3
Sanofi and GSK
Status of clinical trials: Phase 1/2 trials began in September
Sanofi and GSK planned to begin a Phase 3 trial in December, but on Dec. 11 the companies said they suffered a setback based on early data. Sanofi’s global medical head for vaccines told STAT News the problem relates to “inadequate results in older adults” from its candidate, which the company traced back to “an inadequate formulation of their vaccine.”
The companies plan to begin another Phase 2 trial in February, and a Phase 3 study could start in the second quarter of 2021. The setback will push the estimated timeline for distribution of the Sanofi-GSK vaccine from the first half of 2021 into the second half of the year, pending authorization.
Amid delays in Sanofi’s vaccine timeline, the French government has been pressing Sanofi to manufacture vaccines from its rivals. On Jan. 27, agreed to make 125 million doses of the Pfizer-BioNTech vaccine.
Approach: The vaccine candidate builds on work the French drug giant did in the SARS epidemic and employs technology Sanofi used in one of its flu vaccines. Sanofi is using one of GSK’s proprietary adjuvants, an ingredient for vaccines that can create stronger and longer-lasting immunity.
Funding: BARDA has provided $30 million in funding and the US government’s Operation Warp Speed is providing up to $2.1 billion.
Updated Jan. 27
Efficacy: more than 50 percent
Dose: 2 shots, 2 weeks apart
At the end of December, the vaccine developed by the Chinese pharmaceutical firm was found to be more than 50 percent effective in a Brazilian clinical trial, but researchers delayed releasing more information at the request of Sinovac.
On Sept. 16, Sinovac submitted an application for a Phase 1/2 trial of the vaccine candidate in children. Sinovac signed a manufacturing deal to supply Indonesia with at least 40 million doses by March if the vaccine is approved.
Approach: The Sinovac vaccine, called CoronaVac, uses a whole coronavirus that has been inactivated, so that it will trigger an immune response without causing illness. Unlike most of the other vaccine candidates under study, this is a proven vaccine method. But such vaccines, which must be grown in cultures, take longer to manufacture than those based on the virus’s genetic material.
Funding: This spring, Sinovac received $15 million in private investment, as well as an $8.5 million loan from the Bank of Beijing.
Updated Dec. 24
Sanofi and Translate Bio
Status of clinical trials: Preclinical, or not yet being tested in people
Approach: The companies are collaborating on messenger RNA vaccines in a partnership that expands on a 2018 deal to develop such vaccines for as many as five infectious diseases. Translate specializes in developing mRNA medicines.
Funding: Sanofi is paying Translate $425 million upfront. The companies hope to start a trial of a coronavirus vaccine in the fourth quarter of 2021.
Updated July 28
Merck and IAVI
Status of clinical trials: Merck & Co. announced in January it was discontinuing development of its two experimental Covid-19 vaccines after early trial data showed they failed to generate immune responses comparable to a natural infection or existing vaccines.
Approach: The drug giant was partnering with the nonprofit IAVI on a coronavirus vaccine related to the company’s existing Ebola vaccine.
Funding: BARDA had provided $38 million.
Updated Jan. 25
Status of clinical trials: Preclinical, or not yet being tested in people
Approach: A subsidiary of the Swiss pharmaceutical giant Novartis is collaborating with Massachusetts Eye and Ear and Massachusetts General Hospital on a vaccine that uses a harmless virus as a Trojan horse to deliver the genetic sequence of the coronavirus into human cells to produce an immune response.
Funding: The collaboration has received a $1 million donation from Boston Celtics co-owner Wyc Grousbeck.
Updated Jan. 5
Design by Ryan Huddle/Globe staff.
Felice J. Freyer can be reached at email@example.com. Follow her on Twitter @felicejfreyer. Jonathan Saltzman can be reached at firstname.lastname@example.org. Anissa Gardizy can be reached at email@example.com. Follow her on Twitter @anissagardizy8.